Markers of Vascular Function in Hypertension due to Cushing’s Syndrome

Abstract

Background: There are limited data regarding the role of vascular endothelial growth factor (VEGF) in arterial hypertension. The aim of the study was to determine some markers of vascular function, including VEGF, active renin and prostaglandin E₂ (PGE₂) in patients with endocrine hypertension resulting from Cushing’s syndrome. Material and Methods: The study comprised 32 patients with active Cushing’s syndrome, 22 patients with essential hypertension, and 24 healthy volunteers. Results: VEGF was significantly elevated in the groups of patients compared to controls. VEGF levels in the patients with Cushing’s syndrome were significantly higher than in patients with essential hypertension. We did not find significant differences in VEGF levels between patients with Cushing’s disease and Cushing’s syndrome due to adrenal tumor. Active renin and PGE₂ levels did not differ significantly among groups. Conclusion: VEGF levels were significantly elevated in endocrine hypertension due to glucocorticoid excess. Higher VEGF levels were detected in patients with Cushing’s syndrome compared to patients with essential hypertension. Based on our results, we could not judge the extent to which this VEGF elevation in the patients with Cushing’s syndrome was due to the hypertension itself and/or to the presence of adrenal tumor/hyperplasia.

Vascular endothelial growth factor - Hypertension - Angiogenesis - Cushing’s syndrome

References

• 1 Katoh R. Angiogenesis in endocrine glands: special reference to the expression of vascular endothelial growth factor.  Microsc Res Tech. 2003;  60 181-185
• 2 Ferrara N, Davis-Smyth T. The Biology of Vascular Endothelial Growth Factor.  Endocr Rev. 1997;  18 4-25
• 3 Ku D D, Zaleski J K, Liu S Y, Brock T A. Vascular endothelial growth factor induced EDRF-dependent relaxation in coronary arteries.  Am J Physiol. 1993;  256 H586-592
• 4 van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C, Isner J M. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium.  Circulation. 1997;  95 1030-1037
• 5 Hariawala M D, Horowitz J R, Esakof D, Sheriff D D, Walter D H, Keyt B, Isner J M, Symes J F. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts.  J Surg Res. 1996;  63 77-82
• 6 Horowitz J, Hariawala M, Sheriff D D, Keyt B, Symes J F. In vivo administration of vascular endothelial growth factor is associated with EDRF-dependent decrease in systemic hypotension in porcine and rabbit.  Circulation. 1995;  92 I-630
• 7 Yang R, Thomas G R, Bunting S, Ko A, Ferrera N, Keyt B, Ross J, Jin H. Effects of vascular endothelial growth factor on hemodynamic and cardiac performance.  J Cardiovasc Pharmacol. 1996;  27 838-844
• 8 Eppler S M, McCluskey E R, Henry T D, Simons M, Giordano F J, Zioncheck T F. Unique kinetics and hemodynamics of vascular endothelial growth factor (rhVEGF) following intracoronary and intravenous infusion in humans.  J Am Coll Cardiol. 2000;  35 (suppl A) 37A
• 9 Liu M H, Jin H K, Floten H S, Yang Q, Yim A P, Furnary A, Zioncheck T F, Bunting S, He G W. Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats.  J Pharmacol Exp Ther. 2001;  296 473-477
• 10 Belgore F M, Blann A D, Li-Saw-Hee F L, Beevers D G, Lip G Y. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension.  Am J Cardiol. 2001;  87(6) 805-807
• 11 Pai R, Szabo I L, Soreghan B A, Atay S, Kawanaka H, Tarnawski A S. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways.  Biochem Biophys Res Commun. 2001;  286 923-928
• 12 Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.  Ann Clin Lab Sci. 2001;  31(4) 325-348
• 13 Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor.  Am J Physiol Heart Circ Physiol. 2001;  280(2) H885-891
• 14 Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M, Misciglia N, Mavilia C, Vellei U, Villari D, Serio M. Angiotensin II Stimulates the Synthesis and Secretion of Vascular Permeability Factor/Vascular Endothelial Growth Factor in Human Mesangial Cells.  J Am Soc Nephrol. 1999;  10 245-255
• 15 Kiefer F N, Neysari S, Humar R, Li W, Munk V C, Battegay E J. Hypertension and angiogenesis.  Curr Pharmaceut Design. 2003;  9 1733-1744
• 16 Levy B I, Ambrosio G, Pries A R, Struijker-Boudier H A. Microcirculation in hypertension: a new target for treatment?.  Circulation. 2001;  104 735-740
• 17 Felmeden D C, Spencer C G, Belgore F M, Blann A D, Beevers D G, Lip G Y. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management.  Am J Hypertens. 2003;  16 11-20
• 18 Felmeden D C, Spencer C G, Blann A D, Beevers D G, Lip G Y. Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).  J Intern Med. 2003;  253 81-91
• 19 Cucina A, Borrelli V, Randone B, Coluccia P, Sapienza P, Cavallaro A. Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells.  J Surg Res. 2003;  109 16-23
• 20 Katoh R. Angiogenesis in endocrine glands: special reference to the expression of vascular endothelial growth factor.  Microsc Res Tech. 2003;  60(2) 181-185
• 21 Bernini G P, Moretti A, Bonadio A G, Menicagli M, Viacava P, Naccarato A G, Iacconi P, Miccoli P, Salvetti A. Angiogenesis in human normal and pathologic adrenal cortex.  J Clin Endocrinol Metab. 2002;  87 4961-4965
• 22 Thomas M, Keramidas M, Monchaux E, Feige J J. Role of adrenocorticotropic hormone in the development and maintenance of the adrenal cortical vasculature.  Microsc Res Tech. 2003;  61 247-251
• 23 Heikkila P, Arola J, Voutilainen R, Salmenkivi K, Kahri A L, Liu J. Expression of vascular endothelial growth factor in human adrenals.  Endocr Res. 2000;  26 867-871
• 24 Gaillard I, Keramidas M, Liakos P, Vilgrain I, Feige J J, Vittet D. ACTH-regulated expression of vascular endothelial growth factor in the adult bovine adrenal cortex: a possible role in the maintenance of the microvasculature.  J Cell Physiol. 2000;  185 226-234
• 25 Yamada S, Takada K. Angiogenesis in pituitary adenomas.  Microsc Res Tech. 2003;  60(2) 236-243
• 26 Hunter J A, Skelly R H, Aylwin S J, Geddes J F, Evanson J, Besser G M, Monson J P, Burrin J M. The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.  Eur J Endocrinol. 2003;  148(2) 203-211
• 27 Salcedo R, Zhang X, Young H A, Michael N, Wasserman K, Ma W H, Martins-Green M, Murphy W J, Oppenheim J J. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells.  Blood. 2003;  Jun 5 [Epub ahead of print]
• 28 Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth.  J Clin Invest. 2003;  112 67-75
• 29 Volpert O V, Ward W F, Lingen M W, Chesler L, Solt D B, Johnson M D, Molteni A, Polverini P J, Bouck N P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.  J Clin Invest. 1996;  98 671-679
• 30 Takeshita S, Tomiyama H, Yokoyama N, Kawamura Y, Furukawa T, Ishigai Y, Shibano T, Isshiki T, Sato T. Angiotensin converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats.  Cardiovasc Res. 2001;  52 314-320